Crossref Citations
This article has been cited by the following publications. This list is generated based on data provided by Crossref.
Facey, Karen M.
Espin, Jaime
Kent, Emma
Link, Angèl
Nicod, Elena
O’Leary, Aisling
Xoxi, Entela
van de Vijver, Inneke
Zaremba, Anna
Benisheva, Tatyana
Vagoras, Andrius
and
Upadhyaya, Sheela
2021.
Implementing Outcomes-Based Managed Entry Agreements for Rare Disease Treatments: Nusinersen and Tisagenlecleucel.
PharmacoEconomics,
Vol. 39,
Issue. 9,
p.
1021.
Blonda, Alessandra
Denier, Yvonne
Huys, Isabelle
Kawalec, Pawel
and
Simoens, Steven
2022.
How Can We Optimize the Value Assessment and Appraisal of Orphan Drugs for Reimbursement Purposes? A Qualitative Interview Study Across European Countries.
Frontiers in Pharmacology,
Vol. 13,
Issue. ,
Tafuri, Giovanni
Bracco, Andrea
and
Grueger, Jens
2022.
Access and pricing of medicines for patients with rare diseases in the European Union: an industry perspective.
Expert Review of Pharmacoeconomics & Outcomes Research,
Vol. 22,
Issue. 3,
p.
381.
Whittal, Amanda
Jommi, Claudio
De Pouvourville, Gérard
Taylor, David
Annemans, Lieven
Schoonaert, Lies
Vermeersch, Sebastian
Hutchings, Adam
and
Patris, Julien
2022.
Facilitating More Efficient Negotiations for Innovative Therapies: A Value-Based Negotiation Framework.
International Journal of Technology Assessment in Health Care,
Vol. 38,
Issue. 1,
Rezende, Jennifer
and
Mendes, Samara Jamile
2023.
Avaliação de tecnologia em saúde para as doenças raras.
JMPHC | Journal of Management & Primary Health Care | ISSN 2179-6750,
Vol. 15,
Issue. spec,
p.
e036.
Drummond, Michael
Ciani, Oriana
Fornaro, Giulia
Jommi, Claudio
Dietrich, Eva Susanne
Espin, Jaime
Mossman, Jean
and
de Pouvourville, Gerard
2023.
How are health technology assessment bodies responding to the assessment challenges posed by cell and gene therapy?.
BMC Health Services Research,
Vol. 23,
Issue. 1,
Farris, Maria
Goodall, Stephen
and
De Abreu Lourenco, Richard
2023.
A systematic review of economic evaluations for RPE65-mediated inherited retinal disease including HTA assessment of broader value.
International Journal of Technology Assessment in Health Care,
Vol. 39,
Issue. 1,
Vargas, Constanza
De Abreu Lourenco, Richard
Espinoza, Manuel
and
Goodall, Stephen
2024.
Systematic Literature Review of Access Pathways to Drugs for Patients with Rare Diseases.
Applied Health Economics and Health Policy,
Uwitonze, Jean Pierre
Duminy, Lize
and
Blankart, Carl Rudolf
2024.
Identifying health inequities faced by older adults with rare diseases: A systematic literature review and proposal for an ethical spectrum and resource allocation framework.
Health Policy,
Vol. 149,
Issue. ,
p.
105176.
Felippini, Arturo
Biglia, Luiza Vasconcelos
Lima, Tácio de Mendonça
and
Aguiar, Patricia Melo
2024.
HTA criteria adopted in different models of public healthcare systems for orphan drugs: A scoping review.
Health Policy,
Vol. 144,
Issue. ,
p.
105080.
Shen, Guobo
Liu, Jian
Yang, Hanmei
Xie, Na
and
Yang, Yang
2024.
mRNA therapies: Pioneering a new era in rare genetic disease treatment.
Journal of Controlled Release,
Vol. 369,
Issue. ,
p.
696.
Angell, Blake
Wang, Siyuan
Gadsden, Thomas
Moorthy, Monica
Malik, Charu
Barratt, Jonathan
Devuyst, Olivier
Ulasi, Ifeoma I.
Gale, Daniel P.
Sengupta, Agnivo
Palagyi, Anna
Jha, Vivekanand
and
Jan, Stephen
2024.
Scoping Review of Economic Analyses of Rare Kidney Diseases.
Kidney International Reports,
Vol. 9,
Issue. 12,
p.
3553.